Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 24,900 shares, an increase of 1,055.5% from the January 15th total of 2,155 shares. Approximately 16.6% of the shares of the company are sold short. Based on an average daily trading volume, of 3,724 shares, the days-to-cover ratio is currently 6.7 days. Based on an average daily trading volume, of 3,724 shares, the days-to-cover ratio is currently 6.7 days. Approximately 16.6% of the shares of the company are sold short.

Institutional Trading of Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC boosted its holdings in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,891 shares of the company’s stock after acquiring an additional 1,215 shares during the quarter. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 as of its most recent SEC filing.

Amplify Weight Loss Drug & Treatment ETF Trading Down 0.3%

Shares of THNR traded down $0.08 during trading hours on Tuesday, reaching $26.04. 946 shares of the stock traded hands, compared to its average volume of 4,413. The company has a market cap of $3.91 million, a P/E ratio of 24.31 and a beta of 0.61. The company’s 50-day moving average price is $25.78 and its two-hundred day moving average price is $24.37. Amplify Weight Loss Drug & Treatment ETF has a 52-week low of $18.56 and a 52-week high of $27.28.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The business also recently disclosed an annual dividend, which was paid on Wednesday, December 31st. Stockholders of record on Tuesday, December 30th were given a dividend of $0.4132 per share. The ex-dividend date was Tuesday, December 30th. This represents a dividend yield of 162.0%.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.